Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

Tetsuro Miyazaki*, Kazunori Shimada*, Katsumi Miyauchi, Atsumi Kume, Kosei Tanimoto, Takashi Kiyanagi, Katsuhiko Sumiyoshi, Makoto Hiki, Hiroshi Mokuno, Shinya Okazaki, Hitoshi Sato, Takeshi Kurata, Hiroyuki Daida

Abstract

Background: The association between modulation of detailed lipoprotein profiles and cholesterol ester transfer (CET) activity by peroxisome proliferator-activated receptor (PPAR)-a agonists in patients with coronary artery disease remains unclear. We assessed lipid profiles, plasma CET activity, and in-stent intimal hyperplasia after fenofibrate treatment in patients who underwent elective coronary stenting.

Methods: Forty-three consecutive patients who underwent elective coronary stenting were randomized to the fenofibrate group (300 mg/day for 25 weeks, n = 22) or the control group (n = 21). At baseline and follow up, CET activity and lipoprotein profiles were measured, and quantitative coronary angiography was performed.

Results: In the fenofibrate group, the levels of large very low-density lipoprotein cholesterol, and small low-density lipoprotein (LDL) cholesterol decreased and those of small high-density lipoprotein (HDL) cholesterol increased. Besides, CET activity decreased independent of the effect of fenofibrate on total and LDL cholesterol. The reduction of CET activity significantly correlated with the increase in LDL particle size (r = 0.47, P = 0.03) and the decrease of triglycerides in large HDL subclasses (r = 0.48, P = 0.03). Although there were no significant differences in restenosis parameters between the two groups, low CET activity significantly correlated with the inhibition of neointimal hyperplasia (r = 0.56, P = 0.01).

Conclusions: Fenofibrate inhibited CET activity and thereby improved atherogenic lipoprotein profiles, and reduced intimal hyperplasia after coronary stenting.

Background

Fibrates, which act as peroxisome proliferator-activated receptor (PPAR)-a agonists, are widely used in the treatment of atherogenic dyslipidemia. These drugs reduce triglycerides, raise high-density lipoprotein (HDL) cholesterol, and improve the small, dense low-density lipoprotein (LDL) phenotype [1]. Several clinical trials have demonstrated the therapeutic efficacy of fibrates in reducing cardiovascular events in patients with dyslipidemia, which predominates in patients with type 2 diabetes and metabolic syndrome [2-4]. Cholesterol ester transfer protein (CETP) plays an important role in lipoprotein metabolism, including transfer of cholesteryl ester and triglycerides between HDL and apolipoprotein B (apoB)-containing lipoproteins [5]. CETP inhibition leads to increased levels of HDL cholesterol, which contributes to prevent the initiation and progression of atherosclerosis. Indeed, CETP inhibitors have been investigated for clinical use [6,7], although controversy has also arisen [8]. CETP inhibition also results in an increase of anti-inflammatory and anti-oxidative properties of HDL conferred by apoA-1, paraoxonase 1 and platelet activating factor-acetylhydrolase [9-11]. These findings suggest CETP inhibition could be the target of treatment to prevent...
atherosclerotic diseases. Several studies reported that fibrates increased lipoprotein lipase activity and decreased plasma cholesterol ester transfer (CET) activity in subjects with hypertriglyceridemia and in human CETP transgenic mice [12-15]. However, the association between modulation of lipoproteins and CET activity by fenofibrate regarding the initiation and progression of atherosclerosis remains unclear.

Nowadays, in-stent restenosis remains a critical problem despite the use of newly developed drug-eluting stents [16]. Until recently, several trials using fibrates have been conducted [2-4]; however, few studies have reported a reduction of the occurrence of in-stent restenosis [17]. We have demonstrated that fenofibrate ameliorates early inflammatory responses, resulting in reduced neointimal hyperplasia after coronary stenting in a porcine model [18]. PPAR-a inhibits the expression of proinflammatory genes in a ligand-dependent manner [19,20]. In animal models, PPAR-a also inhibits intimal hyperplasia by inhibiting vascular cell recruitment and smooth muscle cell proliferation [21,22]. These results indicated the potential efficacy of fenofibrate in preventing in-stent intimal hyperplasia. In this study, we assessed the lipoprotein profile, CET activity, and intimal intimal hyperplasia before and after fenofibrate treatment in patients who underwent elective coronary stenting.

Methods

Subjects

The subjects were 43 prospectively enrolled patients who underwent elective percutaneous coronary stenting at Juntendo University Hospital. Patients were randomized to the fenofibrate group (300 mg/day for 25 weeks, n = 22) or the control group (n = 21) after diagnostic coronary angiography. Randomization was undertaken to match the two groups for age, gender, body mass index (BMI), baseline lipid profiles, and presence of diabetes mellitus. All patients were instructed to follow the American Heart Association Step II diet. Fenofibrate treatment was initiated a week before coronary stenting. Before and after treatment, lipoprotein profiles and CET activity were assessed. Repeated coronary angiography was performed at baseline, just after coronary stenting and 24 weeks after coronary stenting (25-week treatment). We excluded patients with acute coronary syndrome, ongoing congestive heart failure, liver dysfunction and/or renal dysfunction. The study protocol was approved by the ethical committee of our hospital and all the patients gave their informed consent in writing.

Blood sampling and biochemical analyses

Plasma samples were obtained immediately before coronary angiography after overnight fasting, both at baseline and after treatment. Plasma levels of total cholesterol, triglycerides, HDL cholesterol, HbA1c, and high-sensitivity C-reactive protein (hs-CRP) were measured by standard methods; LDL cholesterol levels were calculated by Friedewald’s formula as previously described [23]. CET activity was measured using commercially available CETP activity assay kits (BioVision Inc, Mountain view, CA). Briefly, the CETP activity assay kit uses a donor molecule that contains a fluorescent self-quenched neutral lipid that is transferred to an acceptor molecule in the presence of CETP. CETP-mediated transfer of the fluorescent neutral lipid to the acceptor molecule results in an increased fluorescence. The value for HbA1c (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA1c (%) = HbA1c (JDS) (%) + 0.4%, considering the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) [24].

Analysis of lipoprotein profiles

Cholesterol and triglyceride profiles in plasma lipoproteins were analyzed using the LipoSEARCH system, which is a dual-detection high performance liquid chromatography (HPLC) system with two tandem-connected TSKgel LipopropakXL columns (300 × 7.8-mm; Tosoh, Japan), at Skylight Biotech Inc. (Akita, Japan), as we and others have previously described [25,26]. We obtained the cholesterol and triglyceride levels in 20 lipoprotein subclasses according to lipoprotein particle diameter. To simplify the data analysis, we grouped some of the subclasses to yield the following 13 subclass categories: chyomicron (peak 1: > 90 nm and 2: 75 nm), large very low-density lipoprotein (VLDL) (peak 3: 64 nm, 4: 53.6 and 5: 44.5 nm), medium VLDL (peak 6: 36.8 nm), small VLDL (peak 7: 31.3 nm), large LDL (peak 8: 28.6 nm), medium LDL (peak 9: 25.5 nm), small LDL (peak 10: 23.0 nm), very small LDL (peak 11: 20.7 nm, 12: 18.6 nm and 13: 16.7 nm), very large HDL (peak 14: 15.0 nm and 15: 13.5 nm), large HDL (peak 16: 12.1 nm), medium HDL (peak 17: 10.9 nm), small HDL (peak 18: 9.8 nm), and very small HDL (peak 19: 8.8 nm and 20: 7.6 nm). The average particle diameter (nm) of LDL was obtained from the LDL peak time by HPLC.

Angiographic methods

Coronary angiography and bare metal implantation were performed according to standard methods [27]. After intracoronary injection of isosorbide dinitrate, angiograms were obtained in 2 or more views. The technical aspects of the procedure, including the choice of bare stent and balloon, duration of inflation and pressure, were determined by each operator. Cardiac imaging system (Cardiovascular Angiography Analysis System,
CAAS, Limburg, Netherlands) was used for the quantitative coronary angiography (QCA) analysis. A technician without any knowledge of the study results performed all the QCA analyses. The absolute values for the mean reference diameter and minimal luminal diameter (MLD) were determined. Percent diameter stenosis (MLD/reference), late lumen loss (MLD post minus MLD at follow-up), and loss index (late lumen loss/acute gain) were calculated. We obtained data from 19 patients in each group.

Statistical analysis
The primary objective of the study was to assess the effect of fenofibrate on in-stent intimal hyperplasia, including minimal luminal diameter, diameter stenosis, and late lumen loss at the follow-up angiography. The secondary objectives were the effects on angiographic stenosis defined as a diameter stenosis ≥ 50% at the follow-up angiography as determined by QCA analysis; CET activity; and changes in lipid profiles defined by HPLC analysis. Data are presented as the mean ± SD. Statistical differences between the two groups were analyzed by unpaired Student’s t-test and chi-square test. Statistical differences between baseline and post-treatment values were analyzed by paired Student’s t-test. Correlation between two parameters was determined by simple linear regression analysis. The statistical analysis was performed using StatView software (Version 5.0 for Windows, SAS Institute, Cary, NC). The level of statistical significance was set at P < 0.05.

Results
Patient characteristics at baseline and after treatment
The characteristics of the patients at baseline and follow up are shown in Table 1. There were no significant differences in age, gender, BMI, lipid profiles, HbA1c, hs-CRP, CET activity, prevalence of diabetes mellitus and hypertension, and smoking history between the two groups at baseline. Besides, there were no significant differences between the two groups in the number of patients taking other medications, such as b-blockers (52 vs. 41%), calcium channel blockers (38 vs. 59%), angiotensin II receptor blockers (19 vs. 9%), angiotensin converting enzyme inhibitors (29 vs. 18%), statins (48 vs. 32%) or oral hypoglycemic drugs (19 vs. 18%) throughout the study period. Total and LDL cholesterol levels decreased by 9.5% (P = 0.01) and 12.5% (P = 0.01) in the control group and by 9.5% (P = 0.02) and 13.5% (P = 0.02) in the fenofibrate group. There were no significant differences in total and LDL cholesterol levels between the two groups at follow up. Fenofibrate treatment resulted in a decrease of triglyceride levels by 32.1% (P < 0.0001) and an increase of HDL cholesterol levels by 8.7% (P = 0.03) whereas no change in triglyceride or HDL cholesterol levels occurred in the control group. There were no significant changes in BMI, HbA1c or hs-CRP in either group. CET activity decreased by 30.5% in the fenofibrate group (P < 0.05) but it remained unchanged in the control group.

Effect of fenofibrate on lipoprotein subclass profiles
Table 2 shows the changes in lipoprotein profiles analyzed by HPLC after treatment. Fenofibrate significantly decreased cholesterol levels in the chylomicron, large and medium VLDL subclasses, whereas the control group showed a significant decrease of cholesterol levels in the medium and small VLDL subclasses. Fenofibrate also significantly decreased cholesterol levels in the medium, small and very small LDL subclasses, however, there were no significant changes of cholesterol levels in any LDL subclass in the control group. In addition, fenofibrate significantly increased cholesterol levels in the medium, small and very small HDL subclasses and significantly decreased very large HDL cholesterol levels. On the contrary, the control group showed a significant increase of cholesterol levels in the very large and large HDL subclasses. Fenofibrate significantly reduced triglyceride levels in all lipoprotein subclasses except in the small and very small HDL subclasses. At follow up, no significant changes were noted in triglyceride levels in any lipoprotein in the control group.

The LDL particle size increases as CET activity is reduced by fenofibrate
As shown in figure 1A, after fenofibrate treatment the mean LDL particle size increased (25.7 ± 0.6 vs. 26.1 ± 0.2 nm, P < 0.001). Despite the significant decrease in each LDL cholesterol level observed in the two groups, the mean LDL particle size did not change in the control group (25.8 ± 0.7 vs. 25.8 ± 0.6 nm, NS). Figure 1B shows that the increase in mean LDL particle size significantly correlated with the decrease in CET activity in all patients.

Reduction of CET activity correlates with the decrease of triglycerides in larger HDL subclasses
Figure 2 shows the significant, positive correlation between the reduction of CET activity and the decrease of triglyceride levels in very large and large HDL subclasses. This correlation was stronger in the fenofibrate group (r = 0.48, P = 0.03). These results suggest that the reduction of CET activity by fenofibrate may inhibit transfer of triglycerides from apoB-containing lipoprotein to larger HDL subclasses.

Reduction of CET activity by fenofibrate correlates with that of in-stent intimal hyperplasia
Table 3 shows the angiographic characteristics of patients in the two groups. There were no significant...
Table 1 Characteristics of the study population at baseline and at follow up (25 weeks of treatment)

|                         | Baseline (n = 21) |        |  | Follow up (n = 22) |        |  |
|-------------------------|------------------|--------|---|------------------|--------|---|
| Age (years)             | 64 ± 8           |        | 0.33|                   |        |   |
| Male gender (%)         | 16 (76)          |        | 0.65|                   |        |   |
| Diabetic mellitus (%)   | 6 (29)           |        | 0.92|                   |        |   |
| Hypertension (%)        | 11 (52)          |        | 0.88|                   |        |   |
| Current smoker (%)      | 5 (24)           |        | 0.80|                   |        |   |
| Body mass index (kg/m²) | 24.5 ± 2.5       |        | 0.27| 23.7 ± 1.9       | 0.27   |   |
| Total cholesterol (mg/dL)| 199 ± 33         |        | 0.33| 189 ± 31         | 0.33   |   |
| Triglycerides (mg/dL)   | 110 ± 48         |        | 0.75| 106 ± 36         | 0.75   |   |
| HDL cholesterol (mg/dL) | 45 ± 11          |        | 0.84| 46 ± 10          | 0.84   |   |
| LDL cholesterol (mg/dL) | 110 ± 29         |        | 0.32| 102 ± 24         | 0.32   |   |
| Hba1c (%)               | 6.1 ± 1.4        |        | 0.54| 6.3 ± 1.6        | 0.54   |   |
| hs-CRP (mg/L)           | 1.33 ± 1.26      |        | 0.41| 1.93 ± 2.03      | 0.41   |   |
| CET activity (pmol/μL/h)| 88.4 ± 40.7      |        | 0.68| 82.6 ± 50.4      | 0.68   |   |

Data are presented as the mean ± SD. LDL = Low-density lipoprotein, HDL = High-density lipoprotein, hs-CRP = high sensitivity C-reactive protein, CET = cholesterol ester transfer. Statistical differences between the control group and the fenofibrate group were analyzed by unpaired Student’s t-test. Statistical differences between values at baseline and at follow up were analyzed by paired Student’s t-test. Statistical differences were evaluated using the t-test. Statistical differences were evaluated using the t-test. Statistical differences were evaluated using the t-test.

Discussions

PPAR-α agonists decrease the production of atherogenic large VLDL in the liver through the stimulation of fatty acid oxidation and enhance triglyceride degradation in VLDL through the induction of lipoprotein lipase [1]. This reduction of large VLDL subsequently results in a decrease of small, dense LDL particles and an increase of HDL cholesterol [1]. In addition, PPAR-α inhibits the expression of proinflammatory genes in a ligand-dependent manner by inhibiting the action of NF-κB [19,20]. In animal models, PPAR-α also inhibits intimal hyperplasia by inhibiting vascular cell recruitment and smooth muscle cell proliferation [21,22]. Furthermore, several studies showed that PPAR-α agonists decreased CET activity in subjects with hypertriglyceridemia [12-14]. However, the association between the modulation of detailed lipoprotein profiles and CET activity by PPAR-α agonists in patients with coronary artery disease remains unclear. Therefore, we focused on the association of CET activity regulated by PPAR-α agonist, fenofibrate, with the detailed lipoprotein profiles and the development of in-stent restenosis.

Transcription of the CETP gene is induced by a high cholesterol diet in CETP transgenic mice, suggesting that fibrates may reduce CET activity through a decrease in cholesterol levels [28,29]. In our study population, however, only fenofibrate treatment significantly decreased CET activity although similar reductions of total and LDL cholesterol levels were observed in both groups. In addition, absolute changes in total and LDL cholesterol levels did not correlate with CET activity. The binding of PPAR-α to a potential peroxisome proliferator response element in the promoter region of CETP inhibited CETP gene expression [30]. These findings suggest that PPAR-α agonists directly regulated, at least in part, CET activity independent of their effects on cholesterol lowering. HPLC analysis revealed that fenofibrate significantly decreased cholesterol levels in larger VLDL subclasses and smaller LDL subclasses and increased cholesterol levels in smaller HDL subclasses.
These specific changes in lipoprotein profiles, not mere cholesterol levels, also could be associated with a decrease in CET activity.

Reduction of triglycerides in apoB-containing lipoproteins by fibrates leads to an increase in LDL particle size [1]. In this study, however, the decrease in triglyceride levels in any VLDL, LDL and HDL subclass was not significantly correlated with changes in LDL size. Interestingly, the change in CET activity significantly correlated with the increase in mean LDL particle size and the decrease in cholesterol levels in smaller LDL subclasses. Changes in CET activity also correlated with triglyceride levels in larger HDL subclasses, which are the most cardioprotective HDL subclasses [23,31,32]. The reduction of CET activity results in the inhibition of the triglyceride flux from apoB containing lipoprotein to HDL. These large and triglyceride-poor HDL have a longer half-life in plasma than small and triglyceride-rich HDL [1]. Therefore, fenofibrate may inhibit removal of these cardioprotective HDL particles from the circulation through the inhibition of CET activity.

Finally, we investigated the relationship between CET activity and in-stent neointimal hyperplasia after coronary stenting. We found no significant differences in

| Table 2 Effect of fenofibrate on lipoprotein subclass profiles analyzed by HPLC in patients with CAD |
|-----------------------------------------------|-----------------------------------------------|
| Control (n = 21) | Fenofibrate (n = 22) | P | Control (n = 21) | Fenofibrate (n = 22) | P |
|------------------|-------------------|---|------------------|-------------------|---|
| **Cholesterol**  |                   |   |                   |                   |   |
| Chylomicron-C (mg/dL) | 0.9 ± 0.6 | 0.8 ± 0.6 | 0.54 | 0.7 ± 0.6 | 0.5 ± 0.4† | 0.20 |
| Large VLDL-C (mg/dL) | 20.7 ± 6.7 | 20.5 ± 7.2 | 0.93 | 17.8 ± 6.3 | 16.1 ± 6.4† | 0.41 |
| Medium VLDL-C (mg/dL) | 160 ± 50 | 138 ± 38 | 0.11 | 133 ± 49* | 119 ± 33* | 0.28 |
| Small VLDL-C (mg/dL) | 94.2 ± 26 | 85.2 ± 22 | 0.23 | 81.2 ± 24* | 83.2 ± 22 | 0.72 |
| Large LDL-C (mg/dL) | 20.5 ± 4.7 | 19.8 ± 3.8 | 0.60 | 18.4 ± 5.3 | 19.1 ± 4.6 | 0.68 |
| Medium LDL-C (mg/dL) | 272 ± 6.2 | 269 ± 6.0 | 0.91 | 250 ± 8.2 | 234 ± 6.0* | 0.47 |
| Small LDL-C (mg/dL) | 195 ± 50 | 197 ± 55 | 0.88 | 179 ± 69 | 159 ± 44† | 0.27 |
| Very small LDL-C (mg/dL) | 143 ± 41 | 152 ± 46 | 0.48 | 132 ± 54 | 122 ± 32† | 0.49 |
| Very large HDL-C (mg/dL) | 4.1 ± 1.2 | 4.7 ± 1.5 | 0.14 | 4.6 ± 1.8* | 3.9 ± 1.5* | 0.18 |
| Large HDL-C (mg/dL) | 7.4 ± 3.9 | 8.5 ± 4.1 | 0.37 | 8.8 ± 46* | 7.1 ± 42 | 0.21 |
| Medium HDL-C (mg/dL) | 123 ± 34 | 120 ± 33 | 0.80 | 124 ± 34 | 154 ± 44† | 0.02 |
| Small HDL-C (mg/dL) | 98.2 ± 24 | 93 ± 24 | 0.51 | 98.2 ± 21 | 119 ± 28† | 0.009 |
| Very small HDL-C (mg/dL) | 7.0 ± 1.1 | 7.3 ± 1.8 | 0.46 | 6.9 ± 1.2 | 8.8 ± 1.8† | < 0.001 |
| **Triglycerides**  |                   |   |                   |                   |   |
| Chylomicron-TG (mg/dL) | 1.9 ± 1.4 | 1.7 ± 1.5 | 0.68 | 1.7 ± 2.1 | 0.9 ± 1.0† | 0.14 |
| Large VLDL-TG (mg/dL) | 22.3 ± 4.4 | 26.2 ± 11.5 | 0.15 | 23.7 ± 12.4 | 151 ± 9.5† | 0.01 |
| Medium VLDL-TG (mg/dL) | 9.7 ± 2.3 | 11.0 ± 4.6 | 0.25 | 10.1 ± 40 | 7.4 ± 37† | 0.03 |
| Small VLDL-TG (mg/dL) | 4.6 ± 1.0 | 5.1 ± 2.0 | 0.30 | 4.9 ± 1.7 | 3.8 ± 1.7† | 0.05 |
| Large LDL-TG (mg/dL) | 63.5 ± 1.5 | 66.2 ± 20 | 0.54 | 63.2 ± 20 | 5.7 ± 21* | 0.37 |
| Medium LDL-TG (mg/dL) | 7.2 ± 7.1 | 7.6 ± 1.8 | 0.42 | 6.9 ± 21 | 68 ± 22* | 0.86 |
| Small LDL-TG (mg/dL) | 5.4 ± 1.3 | 6.1 ± 1.7 | 0.13 | 5.1 ± 1.7 | 5.1 ± 1.6† | 0.99 |
| Very small LDL-TG (mg/dL) | 5.0 ± 1.2 | 5.9 ± 1.9 | 0.09 | 4.8 ± 1.7 | 46 ± 1.6† | 0.68 |
| Very large HDL-TG (mg/dL) | 18.8 ± 0.4 | 18.4 ± 0.4 | 0.90 | 19.0 ± 0.6 | 1.2 ± 0.5† | < 0.001 |
| Large HDL-TG (mg/dL) | 2.6 ± 1.1 | 2.9 ± 1.2 | 0.40 | 3.3 ± 1.5 | 1.5 ± 1.0† | < 0.001 |
| Medium HDL-TG (mg/dL) | 42 ± 1.3 | 43 ± 1.2 | 0.77 | 45 ± 1.3 | 3.5 ± 1.5* | 0.03 |
| Small HDL-TG (mg/dL) | 36 ± 1.1 | 37 ± 0.9 | 0.56 | 36 ± 0.9 | 35 ± 1.5 | 0.89 |
| Very small HDL-TG (mg/dL) | 3.2 ± 0.7 | 3.6 ± 0.8 | 0.07 | 3.2 ± 0.7 | 3.2 ± 1.2 | 0.95 |

Data are presented as the mean ± SD. CAD = coronary artery disease, VLDL = Very low-density lipoprotein, LDL = Low-density lipoprotein, HDL = High-density lipoprotein, -C = -cholesterol, -TG = -triglycerides. Statistical differences between the control group and the fenofibrate group were analyzed by unpaired Student’s t-test. Statistical differences between values at baseline and at follow up were analyzed by paired Student’s t-test. *P < 0.05 and †P < 0.01 Baseline vs. Follow up.
Figure 1 (A) Comparison of the mean LDL particle size between the control and fenofibrate groups at baseline (white bar) and at follow up (gray bar). Bars represent the mean ± SD. (B) Correlation between mean LDL particle size and cholesterol ester transfer (CET) activity at baseline and at follow up in the control (white circle) group and fenofibrate (gray circle) group.

Figure 2 Correlation between triglyceride levels in very large (A) and large (B) HDL subclasses and cholesterol ester transfer (CET) activity at baseline and at follow up in the control (white circle) group and fenofibrate (gray circle) group.
angiographical findings between the fenofibrate group and the control group at follow up. However, patients in the Low CET activity subgroup showed a significant lower % diameter stenosis and loss index than patients in the High CET activity subgroup and the control group. Interestingly, CET activity at follow up showed a significant correlation with % diameter stenosis while there were no significant correlations between lipoprotein profiles and angiographic findings. As we and another group have previously demonstrated, arterial injury induces inflammatory responses that play important roles in the occurrence of neointimal hyperplasia at the site of coronary stenting [18,26,33]. CETP inhibition increases apoA-1, paraoxonase 1 and platelet activating factor-acetylhydrolase on HDL, which have anti-inflammatory and antioxidative properties [9-11]. Furthermore, in this study, the reduction of CET activity was associated with a decrease of small LDL that is highly susceptible to oxidation [23]. We speculate that fenofibrate

| Table 3 Lesions and procedural characteristics at the time of intervention and follow-up angiography |
|---|---|---|---|---|---|
| | Control (n = 19) | Fenofibrate (n = 19) | P | Fenofibrate High CET activity (n = 9) | Low CET activity (n = 10) | P |
| **Target vessel** | | | | | | |
| LAD (%) | 6 (42) | 5 (24) | 0.49 | 2 (20) | 3 (27) | 0.93 |
| LCX (%) | 3 (21) | 6 (29) | | 3 (30) | 3 (27) | |
| RCA (%) | 5 (36) | 10 (48) | | 5 (50) | 5 (46) | |
| Complex lesion (%) | 14 (74) | 10 (53) | 0.18 | 6 (67) | 4 (44) | 0.34 |
| Restenosis lesion (%) | 3 (16) | 3 (16) | 1.00 | 1 (11) | 2 (20) | 0.60 |
| **Before stenting** | | | | | | |
| Reference diameter (mm) | 2.67 ± 0.51 | 2.61 ± 0.53 | 0.73 | 2.72 ± 0.61 | 2.60 ± 0.39 | 0.61 |
| Minimal lumen diameter (mm) | 0.44 ± 0.15 | 0.55 ± 0.20 | 0.10 | 0.59 ± 0.21 | 0.53 ± 0.18 | 0.55 |
| Diameter stenosis (%) | 82.8 ± 6.1 | 78.2 ± 8.6 | 0.09 | 77.4 ± 9.4 | 78.6 ± 8.8 | 0.78 |
| Lesion length (mm) | 11.4 ± 4.3 | 13.4 ± 6.2 | 0.40 | 12.9 ± 6.1 | 13.8 ± 6.8 | 0.78 |
| **Procedural data** | | | | | | |
| Maximum balloon pressure (atm) | 12.4 ± 0.7 | 12.3 ± 0.48 | 0.68 | 12.3 ± 0.49 | 12.6 ± 0.48 | 0.80 |
| Balloon to vessel ratio | 1.13 ± 0.21 | 1.16 ± 0.17 | 0.63 | 1.17 ± 0.17 | 1.16 ± 0.18 | 0.88 |
| Stent segment length (mm) | 13.6 ± 3.8 | 13.5 ± 3.8 | 0.90 | 14.3 ± 5.0 | 13.2 ± 2.7 | 0.56 |
| **Immediately after stenting** | | | | | | |
| Minimal lumen diameter (mm) | 2.79 ± 0.65 | 2.56 ± 0.50 | 0.26 | 2.56 ± 0.39 | 2.56 ± 0.59 | 1.00 |
| Diameter stenosis (%) | 9.4 ± 10.8 | 10.5 ± 12.8 | 0.79 | 9.7 ± 9.5 | 11.2 ± 15.4 | 0.80 |
| **Follow-up** | | | | | | |
| Minimal lumen diameter (mm) | 1.57 ± 0.56 | 1.64 ± 0.60 | 0.73 | 1.35 ± 0.62 | 1.90 ± 0.46 | 0.04 |
| Diameter stenosis (%) | 44.3 ± 19.4 | 38.6 ± 22.0 | 0.44 | 51.9 ± 21.6 | 26.6 ± 14.8* | 0.01 |
| Late lumen loss (mm) | 1.22 ± 0.51 | 0.91 ± 0.64 | 0.15 | 1.21 ± 0.61 | 0.64 ± 0.56* | 0.05 |
| Loss index | 0.52 ± 0.23 | 0.44 ± 0.29 | 0.39 | 0.60 ± 0.28 | 0.29 ± 0.23* | 0.02 |
| Restenosis (%) | 5 (26) | 4 (21) | 0.70 | 3 (33) | 1 (10) | 0.21 |

Data are mean ± SD. CET = cholesterol ester transfer. LAD = left anterior descending coronary artery, LCX = left circumflex coronary artery, RCA = right coronary artery. The high CET activity and low CET activity were defined as the upper and lower 50th percentile of CET activity levels at follow-up, respectively. Complex lesion was defined as lesion type B2 and C according to the American College of Cardiology/American Heart Association grading system. Statistical differences of parameters between each group were analyzed by unpaired Student’s t-test. *P < 0.05 and **P < 0.01 vs. control group.
prevents in-stent neointimal hyperplasia through a reduction of CET activity and the subsequent induction of anti-inflammatory and antioxidative lipoprotein profiles.

This study has several limitations. First, the sample size was small, especially in the High and Low CET activity groups. Therefore, we could not perform multivariate analysis to exclude the interaction among lipoprotein subclasses, CET activity and angiographic findings. We believe that the present study is one of the pioneering and valuable reports promoting further investigations. Second, we could not exclude the effects of changes in triglycerides and HDL cholesterol induced by fenofibrate from those on CET activity. However, there were no significant correlations between changes in CET activity and changes in total triglycerides or HDL cholesterol. Third, we did not measure CETP mass in this population. Therefore, whether the reduction of CET activity depends on the production of CETP remains unclear. Fourth, all patients were performed bare metal but not drug-eluting stenting. However, as mentioned above, in-stent restenosis still remains a clinical problem even in drug-eluting stent era [16]. In addition, we did not perform intravascular ultrasound for quantitative assessment in this study. The assessment using intravascular ultrasound is needed in the next step.

Conclusions
In conclusion, fenofibrate decreased CET activity independent of its lowering effect on total and LDL cholesterol in patients with coronary artery disease. That reduction of CET activity significantly correlated with any increase in LDL particle size and a decrease in triglycerides in larger HDL subclasses, besides a decrease in in-stent intimal hyperplasia. Inhibition of CET activity by fenofibrate might be a potent strategy for preventing in-stent intimal hyperplasia after coronary stenting.

Acknowledgements
This work was partially supported by the High Technology Research Center Grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors wish to thank each of the participants for their data collection.

Authors’ contributions
TM participated in planning of the study, experimental work, analysis and prepared the manuscript. KazS contributed in designing of the study, data analysis and publication of results. AK, KaS, and TK participated in lipid analysis and CETA measurement. HM participated in planning of the study and discussion of results. KT, TK, MH, SQ, HS, and TK involved in coronary catheterization. KM and HD contributed in planning of the experiment and discussion of results, and supervised the study. All authors read and approved the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 14 September 2010 Accepted: 25 October 2010
Published: 25 October 2010

References
1. Chapman MJ: Fibrates in 2003: therapeutic action in athereogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
2. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Scheiman G, Wilt TJ, Wittejes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
3. Diabetes Atherosclerosis Intervention Study (DAIS) investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
4. Keetch A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glassou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Etheloom C, Lakko M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849.
5. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesterol ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
6. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield GM, Gutierrez M, Doherty J, Biebergrodt F, Chodakewitz J, Gottesdierer KM, Wagner JA: Effect of the cholesterol ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907-1914.
7. Kobayashi J, Okamoto H, Otabe M, Bajo H, Saito Y: Effect of HDL, from Japanese white rabbit administered a new cholesterol ester transfer protein inhibitor JTT-705, on cholesterol ester accumulation induced by acetylated low density lipoprotein in rabbits. Atherosclerosis 2002, 162:131-135.
8. Barter PJ, Caufield M, Ekstinos M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhry KA, Fisher MR, Tall AR, Brewer B: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109.
9. Zhang S, Fan P, Shimoj E, Xu H, Takeuchi K, Iban C, Saku K: Inhibition of cholesterol ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004, 24:1910-1915.
10. Baoendal RJ, Hovingh GK, El Harchaoui K, Levels JH, Tsimikas S, Pu K, Zwiersman AE, Kuivenhoven JA, Kastelein JJ, Stroes ES: Consequences of cholesterol ester transfer protein inhibition in patients with familial hypoalphalipoproteinaemia. Arterioscler Thromb Vasc Biol 2005, 25: e133-e134.
11. Keftik AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA: Cholesterol ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:706-715.
12. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ: Fenofibrate reduces plasma cholesterol ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Atherosclerosis 2002, 162:131-135.
13. Jonkers IJ, Smelt AH, Hattoni H, Sweek LM, van Gent T, de Man FH, van der Laarse A, van Tol A: Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 2003, 44:1462-1479.
14. Guerin M, Le Goff WS, Friseld E, Schneider S, Milosavojvic D, Bruckert E, Chapman MJ: Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003, 88:3738-3746.
15. van der Hoot CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Prinzen HM, Jukema JW, Havelkes LM, Rensen PC.
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007, 48:1763-1771.

16. Jeremias A, Kirtane A: Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008, 148:234-238.

17. Ishiwata S, Nakanishi S, Nishiyama S, Seki A: Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coron Artery Dis 1995, 6:883-889.

18. Kasai T, Miyazaki Y, Yokoyama T, Alhara K, Daida H: Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis 2006, 188:274-280.

19. Staels B, Koenig W, Helpert M, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:780-793.

20. Delerive P, De Bosscher K, Besnard S, Vandeven Bengehe W, Peter JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054.

21. Seki N, Bujo H, Jiang M, Shibasaki M, Takahashi K, Hashimoto N, Sato Y: A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis 2005, 178:1-7.

22. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Kimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B: PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 2005, 115:3228-3238.

23. Miyazaki T, Shimada K, Sato O, Kotani K, Kume A, Sumiyoshi K, Sato Y, Ohmura H, Watanabe Y, Mokuno H, Daida H: Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis 2005, 179:139-145.

24. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010, 53:450-467.

25. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002, 43:805-814.

26. Yamanagawa N, Shimada K, Miyazaki T, Kume A, Kitamura Y, Sumiyoshi K, Kiyano T, Iesaki T, Inoue N, Daida H: Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. Lipids Health Dis 2008, 7:48.

27. Yokoi H, Daida H, Kubovara Y, Shimakawa H, Takatsuki T, Fujihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamauchi H: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probuloc Angioplasty Restenosis Trial. Int J Cardiol 1997, 55:185-186.

28. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A: Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992, 90:1290-1295.

29. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havkens LM, Rensen PC: Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in apoE3-Leiden mice. Atherosclerosis Thromb Vasc Biol 2006, 26:2552-2559.

30. Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S: Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet. J Lipid Res 2005, 46:2356-2366.

31. Otvos JD, Enejah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:23-29.

32. Asztalos BF, Schaefer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91:12E-17E.

33. Libby P, Ganz P: Restenosis revisited—new targets, new therapies. N Engl J Med 1997, 337:418-419.